Glooko's suite of software solutions includes the Glooko diabetes management platform, EndoTool® Glucose Management System, Glooko XT, and the Glooko Mobile App, reflecting the company's focus on simplifying diabetes and glycemic management for healthcare providers, hospitals and health systems, and people living with diabetes. In May 2026, Glooko was selected as the winner of the "Best Overall MedTech Software" award in the 10th annual MedTech Breakthrough Awards program.
Cyborg Score Rationale
Glooko demonstrates strong clinical validation, market recognition, and strategic positioning across both outpatient and inpatient diabetes care. Recent award recognition (May 2026) and significant funding ($524M raised) indicate solid investor confidence and execution. However, private status limits visibility into financial performance and growth metrics.
Top Insights
Glooko has raised $524M in total funding with backing from strategic investors including Novo Nordisk, indicating strong confidence in the diabetes management digital health market and potential for continued expansion.
In May 2026, EndoTool IV (Glooko's inpatient glucose management system) demonstrated virtual elimination of severe hypoglycemia across 19 hospitals, directly addressing a critical patient safety metric in hospital diabetes care.
Glooko XT launched as a remote patient monitoring solution tailored for French healthcare (2026), signaling international expansion and evidence-based localization strategy beyond the US market.
Named Competitors
Health2Sync — Diabetes management and remote monitoring
Apree Health — Digital diabetes care platform
One Drop — Digital diabetes management platform for remote patient monitoring
Livongo Health — Chronic disease management including diabetes with connected devices
Recent Developments
(May 2026) Won 'Best Overall MedTech Software' award at 2026 MedTech Breakthrough Awards
(May 2026) Chief Medical and Strategy Officer Mark Clements named one of Becker's Healthcare's 2026 'Great leaders in healthcare'
(Early 2026) EndoTool IV data presented at AACE 2026 showed virtual elimination of severe hypoglycemia across 19 hospitals
Open the full interactive Glooko, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.